Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mometasone · 1 trial · 1 indication
The nasal symptoms (sneezing attacks, rhinorrhea, nasal congestion and itching) were rated in 4 grades (+++: 3 points, ++: 2 points, +: 1 point, -: 0 point) based on the evaluation criteria for nasal symptoms. Total possible best score is 0 points, total possible worst score is 12 points.
| Arm | Type | Description |
|---|---|---|
| Mometasone Furoate Placebo (PLAMF) | PLACEBO_COMPARATOR | Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray |
| Fluticasone Propionate Placebo (PLAFP) | PLACEBO_COMPARATOR | Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray |
| Mometasone Furoate (MF) | EXPERIMENTAL | Mometasone furoate nasal spray 200 μg/day(QD) |
| Fluticasone Propionate (FP) | ACTIVE_COMPARATOR | Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID) |
| Name | Type | Description |
|---|---|---|
| Placebo for MF | DRUG | Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks |
| Placebo for FP | DRUG | Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks |
| Mometasone | DRUG | Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks |
| Fluticasone | DRUG | Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks |
Inclusion Criteria: Patients with perennial allergic rhinitis meeting all of the followings. * Patients with symptoms of perennial allergic rhinitis, the severity of which is moderate or severer according to the severity grading provided in the "Guidelines for the Management of Allergic Rhinitis i...
Mometasone is a small molecule corticosteroid used for asthma and perennial allergic rhinitis. In asthma, it is studied as an inhaled corticosteroid, and in perennial allergic rhinitis, it is studied as a nasal spray. It is being developed by Organon & Co. (OGN) and is currently in clinical development.
Mometasone is being developed by Organon & Co., which trades under the ticker OGN. The company is conducting clinical trials of mometasone for respiratory conditions including asthma and perennial allergic rhinitis.
Mometasone is in Phase 2 clinical development for asthma, based on a completed Phase 2 trial. It has also been studied in a completed Phase 3 trial for perennial allergic rhinitis. The drug is investigational and not yet approved.
Mometasone has one completed Phase 2 trial, NCT00666679, which studied inhaled corticosteroid plus montelukast compared with inhaled corticosteroid therapy alone in 134 patients with chronic asthma. It also has a completed Phase 3 trial, NCT00783224, comparing mometasone furoate nasal spray with fluticasone propionate nasal spray in 351 patients with perennial allergic rhinitis.
Mometasone is the drug name, and mometasone furoate is a specific form used in the nasal spray studied for perennial allergic rhinitis. The clinical trials reference mometasone furoate nasal spray, indicating that mometasone furoate is a formulation of mometasone.